Nancy Hemphill

Key takeaways: The approval is supported by positive clinical trial data for both active and chronic thyroid eye disease. Viridian Therapeutics is launching Lumvoa immediately. The FDA approved Lumvoa, a full insulin-like growth factor 1 receptor antagonist, for the treatment of thyroid eye disease, according to a press release from Viridian Therapeutics.

J&J expands parameters for Oasys daily disposable lens for astigmatism June 17, 2026 2 min watch Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Perform cataract surgery midway between anti-VEGF injections Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Time cataract surgery in between anti-VEGF injections, regardless of the interval length.